alexa Additional Resistance to Moxifloxacin and Levofloxacin among MDR-TB Patients with Base Line Resistance to Ofloxacin at a Reference Laboratory | OMICS International| Abstract
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Biotechnol Biomater 2016, Vol 6(3): 239
  • DOI: 10.4172/2155-952X.1000239

Additional Resistance to Moxifloxacin and Levofloxacin among MDR-TB Patients with Base Line Resistance to Ofloxacin at a Reference Laboratory

Vasim Ahmad1, Zeeshan Sidiq1, Himanshu Vashishtha1, Mahmud Hanif1*, Divya Shrivastsava2, Kaushal Dwivedi1, Sanjeev Saini1, Kamal Kishore Chopra1, Vinod Kumar Badireddy1 and Jaideep Bhalla3
1Department of Mycobacteriology, New Delhi Tuberculosis Centre, Jawaharlal Nehru Marg, Delhi Gate, New Delhi-110002, , India
2Department of Life Sciences, Jaipur National University, Jagatpura, Jaipur-302025, Rajasthan, , India
3Maulana Azad Medical College, New Delhi-110002, , India
*Corresponding Author : Mahmud Hanif, Department of Mycobacteriology, New Delhi Tuberculosis Centre. Jawaharlal Nehru Marg, Delhi Gate, New Delhi-110002, India, Tel: 011-23239056, Fax: 011-23210549, Email: [email protected]

Received Date: Jul 23, 2016 / Accepted Date: Jul 30, 2016 / Published Date: Aug 06, 2016

Abstract

Fluoroquinolones are among the most promising antibiotic drugs for Tuberculosis treatment. Although high levels of fluoroquinolone resistance have been detected among many common bacterial pathogens, little is known about the fluoroquinolone resistance of M. tuberculosis especially at the baseline. The present study was thus aimed at determining the profile of resistance against two newer generation fluoroquinolones-Moxifloxacin and Levofloxacin in MDR-TB isolates with baseline resistance to ofloxacin. A total number of 65 isolates (4 XDR and 61 pre-XDR) were subjected to susceptible testing against levofloxacin and two (higher and lower) concentrations of moxifloxacin. 72.3% in addition to being resistant to ofloxacin were also resistant to levofloxacin and lower concentration of moxifloxacin. The increasing use of FQs for the treatment of other bacterial infections has led to increasing resistance to these antimicrobials. Newer generation FQs are promising drugs in the treatment of drugresistant Tuberculosis but care should be taken regarding the rationale use of these drugs for the treatment of other diseases especially when other drugs are available.

Keywords: Mycobacterium tuberculosis, XDR, Fluoroquinolones, Baseline resistance, Drug susceptibility testing

Citation: Ahmad V, Sidiq Z, Vashishtha H, Hanif M, Shrivastsava D, et al. (2016)Additional Resistance to Moxifloxacin and Levofloxacin among MDR-TB Patients with Base Line Resistance to Ofloxacin at a Reference Laboratory. J Biotechnol Biomater 6:239. Doi: 10.4172/2155-952X.1000239

Copyright: © 2016 Ahmad V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 10720
  • [From(publication date): 9-2016 - Nov 29, 2020]
  • Breakdown by view type
  • HTML page views: 10469
  • PDF downloads: 251
Top